Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17841941 | 1.00 | PKM (0.43) | PKMLMNAMGLLPTGS1PTGS2 | |
| SCHEMBL22311913 | 1.00 | PKM (0.43) | PKMLMNAMGLLPTGS1PTGS2 | |
| SCHEMBL17841909 | 1.00 | PKM (0.43) | PKMLMNAMGLLPTGS1PTGS2 | |
| SCHEMBL17841860 | 1.00 | PKM (0.43) | PKMLMNAMGLLPTGS1PTGS2 | |
| SCHEMBL13541914 | 0.89 | LMNA (0.47) | PKMLMNAMGLLSMN1; SMN2NPC1 | |
| SCHEMBL20338051 | 0.88 | LMNA (0.45) | PKMLMNAMGLLSMN1; SMN2NPC1 | |
| SCHEMBL29211729 | 0.88 | PKM (0.40) | PKMLMNAMGLLPTGS1PTGS2 | |
| SCHEMBL20254026 | 0.87 | MGLL (0.47) | PKMLMNAMGLLPTGS1PTGS2 | |
| SCHEMBL16197376 | 0.87 | MGLL (0.47) | PKMLMNAMGLLPTGS1PTGS2 | |
| SCHEMBL1437808 | 0.87 | MGLL (0.47) | PKMLMNAMGLLPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145575-A1 | MACROMOLECULE-SUPPORTED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-05-08 | — | — | US | disclosed |
| US-20250127914-A1 | ANTIBODY-CONJUGATED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-20250057967-A2 | BIS-BENZIMIDAZOLE STING AGONIST IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-20240335557-A1 | BIS-BENZIMIDAZOLE STING AGONIST IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-10-10 | — | — | US | disclosed |
| US-20230263903-A1 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| WO-2023076599-A1 | TLR AGONIST IMMUNOCONJUGATES WITH CYSTEINE-MUTANT ANTIBODIES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076599-A1 | TLR AGONIST IMMUNOCONJUGATES WITH CYSTEINE-MUTANT ANTIBODIES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-4146282-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20220195066-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2022125884-A1 | IMMUNOCONJUGATES COMPRISING AN ANTI-CEA ANTIBODY LINKED BY CONJUGATION TO ONE OR|MORE 8-HET-2- AMINOBENZAZEPINE DERIVATIVES USEFUL IN TREATING CANCER | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125908-A1 | ANTI-PD-L1 IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125904-A1 | ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022036101-A1 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263903-A1 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | KCNJ5, IL5, CYP3A5 | PKM 1482/4885LMNA 4529/4885MGLL 4668/4885 |
| US-20240335557-A1 | BIS-BENZIMIDAZOLE STING AGONIST IMMUNOCONJUGATES, AND USES THEREOF | STING1, BID, MAVS | PKM 2381/4885LMNA 3950/4885MGLL 1364/4885 |
| US-20250145575-A1 | MACROMOLECULE-SUPPORTED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES | BRD4, MUS81, ABCC8 | PKM 277/4885LMNA 998/4885MGLL 3143/4885 |
| US-20220195066-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | EPHX2, FAAH2, CYP8B1 | PKM 4405/4885LMNA 3021/4885MGLL 1365/4885 |
| US-20250127914-A1 | ANTIBODY-CONJUGATED 8-SULFONYL-BENZAZEPINE COMPOUNDS AND THEIR USES | BCR, CD22, IGSF11 | PKM 3317/4885LMNA 4014/4885MGLL 4378/4885 |
| US-20250057967-A2 | BIS-BENZIMIDAZOLE STING AGONIST IMMUNOCONJUGATES, AND USES THEREOF | STING1, MAVS, TBK1 | PKM 2872/4885LMNA 2919/4885MGLL 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.